Summit Chemical (SMCH) — Senior Unsecured Notes 5.75%
Executive Summary
Demo purchase of $100M face of Senior Unsecured Notes 5.75% at 92.0 (cash investment $92.5M): current yield 6.3%, yield to maturity 9.5%. Recommendation: PASS. Credit score 62/100 (Moderate risk). Base-case IRR 10.1%, downside -2.5%, severe -37.8%; probability-weighted IRR -0.7% vs a 12% hurdle; weighted P(default) 45%; severe-case valuation recovery 16%. PASS: Base-case IRR clears hurdle; Expected-cash-flow IRR (probability-weighted) clears hurdle; Downside IRR stays above floor. The return does not compensate for the modelled downside.
Investment Thesis
Entire capital structure matures within 2.5 years. Base-case refinancing is feasible at ~8.5%, but downside coverage drops toward 2x. The unsecured notes at 92 pull to par if refinanced and are well asset-covered, but we need clarity on refinancing plans.
The question: Does a 9.5% yield on a rank-3 unsecured claim compensate for 45% probability-weighted default risk and 84% severe-case loss?
Company Overview
Integrated chlor-alkali and specialty chemical producer with a concentrated 2027–28 maturity stack. HQ Houston, TX; Materials / Commodity & Specialty Chemicals. FY2025A revenue $2.6B, EBITDA $390M (15.0% margin); total debt $1.8B, cash $120M. DEMO DATA
Industry / Market
Chlor-alkali is a cyclical commodity with energy cost exposure; lenders focus on the through-cycle FCF and asset coverage.
Historical Financial Performance
| $M | FY2022A | FY2023A | FY2024A | FY2025A |
|---|---|---|---|---|
| Revenue | $2.5B | $2.7B | $2.6B | $2.6B |
| % growth | 10.2% | -1.9% | -1.9% | |
| Direct costs / COGS | $1.8B | $2.0B | $1.9B | $1.9B |
| Gross profit (NOI for real estate) | $686.0M | $742.5M | $702.3M | $676.0M |
| % margin | 28.0% | 27.5% | 26.5% | 26.0% |
| Operating expenses (cash, adjusted) | $269.5M | $297.0M | $291.5M | $286.0M |
| EBITDA (company-adjusted basis) | $416.5M | $445.5M | $410.8M | $390.0M |
| % margin | 17.0% | 16.5% | 15.5% | 15.0% |
| D&A | $122.5M | $135.0M | $132.5M | $130.0M |
| Share-based compensation | $0.0M | $0.0M | $0.0M | $0.0M |
| EBIT | $294.0M | $310.5M | $278.3M | $260.0M |
| Interest expense | $104.5M | $110.6M | $116.8M | $122.9M |
| EBT | $189.5M | $199.9M | $161.5M | $137.1M |
| Taxes | $47.4M | $50.0M | $40.4M | $34.3M |
| Net income (model basis) | $142.1M | $149.9M | $121.1M | $102.8M |
| Capex | $134.8M | $148.5M | $145.8M | $143.0M |
| Working capital & other cash items | $10.7M | $37.5M | ($7.5M) | ($7.5M) |
| Free cash flow | $119.2M | $98.9M | $115.4M | $97.3M |
Capital Structure
| Tranche | Rank | Secured | Face value | Rate | Maturity | Mark / price |
|---|---|---|---|---|---|---|
| Revolver | 1 | Yes | $100.0M | S+265bp | 2027-12-31 | — |
| First-Lien Term Loan | 1 | Yes | $900.0M | S+385bp | 2028-03-31 | 97.0 |
| Senior Unsecured Notes 5.75% | 3 | No | $750.0M | 5.75% | 2028-10-15 | 92.0 |
Total debt $1.8B (4.5x EBITDA); net debt $1.6B; liquidity $420M; loan-to-value through the target tranche 90%.
Credit Analysis
Net leverage 4.2x, EBITDA / interest 3.17x, FCF / debt 5.6%, DSCR 1.6x, liquidity ratio 3.2x. Score components: Leverage 8/15, Coverage 8/15, Liquidity 10/10, Free cash flow 5/10, Maturity risk 0/10, Margin stability 10/10, Revenue stability 6/8, Asset coverage 10/12, Industry risk 5/10. Score change vs FY2024A (same capital structure): 65 → 62 (Net leverage increased from 4.0x to 4.2x (-0.6 pts, negative); Interest coverage fell from 3.5x to 3.2x (-1.3 pts, negative); FCF / debt fell from 6.6% to 5.6% (-0.7 pts, negative)).
Debt Maturity Profile
| Period | Debt due | % of debt | Projected liquidity (Base) | Refinancing requirement |
|---|---|---|---|---|
| FY2027E | $100M | 6% | $595M | — |
| FY2028E | $1.6B | 94% | $698M | $952M |
Risk flag: $1650M maturity in FY2028E; only $698M projected liquidity; $952M refinancing requirement.
| Tranche | Matures | Balance at maturity | Cash on hand | Net lev. (test ≤) | Pro-forma coverage (test ≥) | Refi rate | Interest burden after | Result | Resolution |
|---|---|---|---|---|---|---|---|---|---|
| Revolver | FY2027E | $0.0M | $95M | 3.7x (8.5x) | 3.71x (1.20x) | 8.5% | $0.0M | REFINANCING PASS | Repaid from cash |
| First-Lien Term Loan | FY2028E | $873.0M | $186M | 3.3x (8.5x) | 3.15x (1.20x) | 8.5% | $49.6M | REFINANCING PASS | Partly repaid from cash; remainder refinanced |
| Senior Unsecured Notes 5.75% | FY2028E | $750.0M | $186M | 3.3x (8.5x) | 3.15x (1.20x) | 8.5% | $63.8M | REFINANCING PASS | Refinanced |
Base Case
Revenue CAGR 3.0%; FY2030E EBITDA $476M (15.8% margin); trough EBITDA $402M; peak net leverage 3.8x; minimum EBITDA / interest 3.27x; cumulative FCF $548M. No payment default modelled. IRR 10.1%, MOIC 1.21x.
Downside Case
Revenue CAGR -1.3%; FY2030E EBITDA $307M (12.6% margin); trough EBITDA $249M; peak net leverage 6.3x; minimum EBITDA / interest 1.97x; cumulative FCF $110M. Payment default modelled in FY2028E; target-tranche recovery 66%. IRR -2.5%, MOIC 0.91x.
Severe Downside
Revenue CAGR -7.7%; FY2030E EBITDA $156M (9.0% margin); trough EBITDA $94M; peak net leverage 18.5x; minimum EBITDA / interest 0.67x; cumulative FCF ($364M). Payment default modelled in FY2027E; target-tranche recovery 16%. IRR -37.8%, MOIC 0.30x.
Covenant Analysis
| FY2026E | FY2027E | FY2028E | FY2029E | FY2030E | |
|---|---|---|---|---|---|
| Current metric | 3.85x | 3.45x | 3.05x | 2.66x | 2.27x |
| Covenant | ≤ 5.50x | ≤ 5.50x | ≤ 5.50x | ≤ 5.50x | ≤ 5.50x |
| Headroom | 1.65x (30%) | 2.05x (37%) | 2.45x (45%) | 2.84x (52%) | 3.23x (59%) |
| Status | PASS | PASS | PASS | PASS | PASS |
| FY2026E | FY2027E | FY2028E | FY2029E | FY2030E | |
|---|---|---|---|---|---|
| Current metric | 5.52x | 6.34x | 5.90x | 5.43x | 4.96x |
| Covenant | ≤ 5.50x | ≤ 5.50x | ≤ 5.50x | ≤ 5.50x | ≤ 5.50x |
| Headroom | −0.02x (-0%) | −0.84x (-15%) | −0.40x (-7%) | 0.07x (1%) | 0.54x (10%) |
| Status | BREACH | BREACH | BREACH | PASS | PASS |
Recovery Analysis
If the company defaults, recovery value is $1.1B (liquidation) in the severe case → 16% recovery (84% LGD) on the target tranche; downside 66%. Recovery value = MAX(going concern $468M, liquidation $1.1B) + cash, less administrative costs; severe case struck at FY2027E.
| Claim (by seniority) | Rank | Claim | Recovery | Recovery % | Loss | Loss % |
|---|---|---|---|---|---|---|
| Recovery value | $1.1B | |||||
| Less: administrative / DIP costs | ($42.9M) | |||||
| First-Lien Term Loan | 1 | $905.9M | $905.9M | 100.0% | $0.0M | 0.0% |
| Senior Unsecured Notes 5.75% | 3 | $760.8M | $123.7M | 16.3% | $637.1M | 83.7% |
| Total claims | $1.7B | $1.0B | $637.1M | |||
| Equity (residual) | $0.0M | Wiped out | ||||
Investment Returns
| Base Case | Downside | Severe Downside | |
|---|---|---|---|
| Face value / purchase price / cash investment | $100M / 92.0 / $92.5M UNDERWRITING ASSUMPTION | ||
| Cash interest + exit/recovery proceeds | $11.5M + $100.0M | $17.3M + $67.3M | $11.5M + $16.5M |
| Capital gain / (loss) vs purchase price | $8.0M | ($24.7M) | ($75.5M) |
| MOIC | 1.21x | 0.91x | 0.30x |
| IRR (hurdle 12%) | 10.1% | -2.5% | -37.8% |
Key Risks
- Severe-case valuation recovery of 16% is below the 92.0 purchase price: a 84% loss given default.
- Refinancing: $1650M maturity in FY2028E; only $698M projected liquidity; $952M refinancing requirement.
- Downside-case recovery of 66% falls short of the purchase price.
- Severe case produces a payment default in FY2027E.
- Unsecured, rank 3: $1.0B of debt ranks ahead.
Key Protections
- Coverage of 3.17x EBITDA / interest; EBITDA can fall 68% before coverage reaches 1.0x.
- Liquidity of $420M (24% of total debt).
- Base-case refinancing tests pass for all 3 maturing tranche(s); 1 are repaid from cash.
- Pull-to-par on notes at 92
- Refinancing premium/fees
Catalysts
- Refinancing launch
- Chlor-alkali price trend
Due Diligence Items
| Item | Status | Priority | Open question |
|---|---|---|---|
| Historical financials tied to filings | Not Started | High | Do model inputs reconcile to audited statements? |
| Quality of earnings / EBITDA add-backs | In Progress | High | How much of adjusted EBITDA is add-backs? |
| Free cash flow conversion | In Progress | High | What is cash conversion after capex and working capital? |
| Working capital and capex needs | In Progress | Medium | Are capex and working capital run-rates sustainable? |
| Debt documentation review | Issue Identified | High | Priming / drop-down protections and baskets? |
| Covenant package and definitions | Not Started | High | Covenant EBITDA definition and headroom? |
| Maturity profile and refinancing plan | Not Started | High | Is the refinancing plan credible at current leverage? |
| Collateral and lien perfection | Issue Identified | Medium | What assets secure the instrument? |
| Litigation and contingent liabilities | Not Started | Medium | Any material claims ahead of creditors? |
| Guarantees and structural subordination | Not Started | Medium | Which entities guarantee; any non-guarantor leakage? |
| Asset valuation / appraisal support | Not Started | High | Independent value vs assumed asset base? |
| Industry conditions and pricing | In Progress | Medium | Where are we in the industry cycle? |
| Macro and rate sensitivity | In Progress | Low | How does the credit behave at +300 bps? |
Recommendation
PASS. PASS: Base-case IRR clears hurdle; Expected-cash-flow IRR (probability-weighted) clears hurdle; Downside IRR stays above floor. The return does not compensate for the modelled downside.
| Test | Actual | Required | Weight | |
|---|---|---|---|---|
| ✗ | Base-case IRR clears hurdle | 10.1% | ≥ 12.0% | core |
| ✗ | Expected-cash-flow IRR (probability-weighted) clears hurdle | -0.7% | ≥ 12.0% | core |
| ✗ | Downside IRR stays above floor | -2.5% | ≥ 0.0% | core |
| ✓ | Downside recovery meets minimum (valuation waterfall) | 66.3% | ≥ 60.0% | core |
| ✓ | Base-case refinancing succeeds | PASS | PASS | core |
| ✓ | Entry yield meets minimum | 9.5% | ≥ 9.0% | secondary |
| ✓ | Net leverage within maximum | 4.2x | ≤ 6.0x | secondary |
| ✓ | Covenant headroom (base case, minimum) | 30.0% | ≥ 15.0% | secondary |
| ✗ | Principal protected in severe case (recovery ≥ price) | 16 vs 92.0 | recovery ≥ price | secondary |
| ✗ | No unresolved high-priority diligence | 7 open | 0 open | secondary |
What would change my mind?
- EBITDA declines more than 68% from FY2025A (coverage < 1.0x) — or more than 24% (first covenant breaks).
- The entry price is above 89.0: the base case no longer earns the 12% hurdle (assumed price 92.0).
- Severe-case recovery returns the purchase price only if the distressed valuation multiple is at least 17.9x EBITDA (the severe case assumes 5.0x); the question is how much cushion we want.
- Collateral / enterprise value falls more than 7% from the base-case valuation: the tranche starts to take losses.
- Market access weakens: base-case pro-forma coverage at refinancing is 3.71x vs the 1.20x test, at an assumed 8.5% refinancing rate — a higher spread or lower EBITDA flips the test.
Sources (3)
| Source | Document | Data type | Period | Accession | Doc date | Retrieved | Class |
|---|---|---|---|---|---|---|---|
| CreditIQ demo dataset | Summit Chemical — illustrative financial statements FY2022–FY2025 | Income statement / cash flow | FY2022–FY2025 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Summit Chemical — illustrative capital structure & covenants | Debt schedule | As of 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Illustrative indicative bid marks (% of par) | Market price | 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
Generated entirely from the structured model (inputs → analysis → memo): every figure reconciles to the Excel workbook (see Settings → Reconciliation). Hypothetical terms are underwriting assumptions. Not investment advice.